Trials
2 active
4 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Transplantation of autologous dermo-epidermal skin substitute denovoSkin(TM) to the experimental area”In the company’s words, NCT06745557 on ClinicalTrials.gov
- Tested for
- Burns (2 trials)
- Main trialPhase 3
- “This multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in patients with deep partial and full-thickness burns as compared to split-thickness skin.”In the company’s words, NCT06745557 on ClinicalTrials.gov
- Other names
- denovoSkin
Other drugs for Burns
- IP2Birch BioMed Inc · Phase 2/3
- Amniotic Tissue AllograftBardia Anvar · Phase 3
- MW-IIISkingenix, Inc. · Phase 2
- KJ101Shanghai Bao Pharmaceuticals Co., Ltd. · Phase 2
- Microsurfaced split thickness skin graftCellTherX · Marketed (Phase 4 trial)
Coming up1
- 30 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jun 2027 | Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | |
| Phase 2Active, not recruiting | 26 Nov 2025 | Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children | |
| Phase 2Completed | 30 Nov 2022 | Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | |
| Phase 2Completed | 1 Dec 2023 | Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026